



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors

Hong Jiang^a, Wen-Jin Zhang^a, Peng-Hui Li^{a,*}, Jian Wang^b, Chang-Zhi Dong^{a,c}, Kun Zhang^{a,d}, Hui-Xiong Chen^{a,e}, Zhi-Yun Du^{a,*}

^a Institute of Natural Medicine & Green Chemistry, School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China

^b School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China

^c Université Paris Diderot, Sorbonne Paris Cité, ITODYS, UMR 7086 CNRS, 15 rue J-A de Baif, 75270 Cedex 13 Paris, France

^d Wuyi University, Jiangmen 529020, China

^e CNRS, UMR8601, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CBNIT, Université Paris Descartes PRES Sorbonne Paris Cité, UFR Bio5medicale, 45 rue des Saints-Peres, 75270 Paris Cedex 06, France

ARTICLE INFO

Article history:

Received 23 January 2018

Revised 4 March 2018

Accepted 5 March 2018

Available online 6 March 2018

Keywords:

Carbazole

Rhodanine

Topoisomerase II

Cytotoxic

Hybrid molecule

ABSTRACT

In this study, a series of carbazole-rhodanine conjugates was synthesized and evaluated for their Topoisomerase II inhibition potency as well as cytotoxicity against a panel of four human cancer cell lines. Among these thirteen compounds, **3a**, **3b**, **3g**, and **3h** possessed Topoisomerase II inhibition potency at 20 μ M. Mechanism study revealed that these compounds may function as Topo II catalytic inhibitors. It was found that the electron-withdrawing groups on the phenyl ring of compounds played an important role on enhancing both enzyme inhibition and cytotoxicity.

© 2018 Elsevier Ltd. All rights reserved.

Human topoisomerase has been recognized as an important target in anticancer drugs discovery. Two types of topoisomerase exist in humans, namely, type I topoisomerase (Topo I) and type II topoisomerase (Topo II). Both isomers are nuclear enzymes essential to resolve topological problems that occur during DNA transcription, replication, and chromosome segregation.^{1–3} Topo II is the target for several commonly prescribed anticancer drugs, including etoposide, doxorubicin, and mitoxantrone.⁴ Since the identification of amsacrine as a Topo II-targeted anticancer drug in 1984, about 50% of current treatment protocols still employ at least one drug directed against topoisomerases.⁵ However, drug resistance and the severe side effects of Topo II-targeted drugs are an issue.^{6–8} Novel and safer Topo II inhibitors for better anticancer therapeutics are highly active research field.^{9–14}

A hybrid molecule comprising two pharmacophoric groups is often used for the design of new drugs.¹⁵ The hybrid may have increased potencies and/or modified selectivity profiles compared to the corresponding single molecule. Accordingly, several hybrid compounds have been designed, synthesized and identified as

novel Topo II inhibitors (Compounds **1**, **2**, **3**, and **4**; Fig. 1).^{16–19} Our previous studies demonstrated that these conjugates were generally more potent activity than the individual molecule alone (Compounds **5** and **6**; Fig. 1).^{20,21} Continuing with our interest in searching novel anticancer agents that targeting Topo II with high potency, we designed and synthesized novel carbazole-rhodanine conjugates, which contain biologically active carbazole and rhodanine moiety, as shown in Fig. 2.

Carbazole are of great interest due to their broad spectrum of biochemical effects and pharmaceutical functions, including anti-malarial, antibacterial and antitumor activity.²² In particular, there have been intense research efforts in recent years in the design and development of carbazole derivatives as a new class of Topo II inhibitors.^{21,23,24} For example, compounds **7**, **8**, and **9** (Fig. 2) are function as potential Topo II inhibitors and display high cytotoxicity against human cancer cell lines.^{25–27}

Another pharmacophoric group in the target compounds is rhodanine moiety, which has been reported to present a variety of pharmacological activities, including antibacterial, antiparasitic, anti-microbial, and anticancer.²⁸ In recent years, a lot of efforts have focused on the anticancer activity of rhodanine compounds. For example (Fig. 2), GSK1059615 (compound **10**) is a reversible inhibitor of PI3K α , which shows potential anticancer activity.²⁹

* Corresponding authors.

E-mail addresses: liphsiming@163.com (P.-H. Li), zhiyundu@gdut.edu.cn (Z.-Y. Du).




Fig. 1. Hybrid molecule as novel Topo II inhibitors.

Compound **11** displays significant anti-proliferation activity against several cancer cell lines.³⁰

In the previous study, we reported a series novel Topo II inhibitors via a pharmacophore hybridization strategy.^{20,21,31,32} We found that carbazole derivatives containing chalcone analogs displayed strong Topo II inhibition potency and antiproliferation activity. The SAR study revealed that the benzyl group with different substituent linked to carbazole play an important role on the activity.²¹ To pursue our mission to promote novel anticancer agents that target Topo II with high potency, we introduced carbazole and rhodanine moiety into a new hybrid scaffold and linked the benzyl groups with different substituent to carbazole (Fig. 2). We found that these newly synthesized compounds displayed

potent Topo II inhibitory activity and cytotoxic activity against four human cancer cell lines.

The synthetic route of carbazole-rhodanine conjugates is shown in Scheme 1. *N*-alkylation of carbazole was carried out with appropriate benzyl bromides in the presence of KOH to form **1a–1m** in 53–84% yields. The *N*-substituted-9*H*-3-carbaldehydes (**2a–2m**) were synthesized from **1a** to **1m** through Vilsmeier-Haack reaction in 63–87% yields. The target compounds **3a–3m** were synthesized from **2a** to **2m** through the Horner-Wadsworth-Emmons reaction of rhodanine moiety in 66–91% yield. The synthesized compounds were characterized by ¹H NMR, ¹³C NMR, IR, and HRMS (ESI), which was in full accordance with their depicted structures and the structure of these compounds are shown in Table 1.

The resulting synthetic **3a–3m** were evaluated for their cytotoxic activities against human lung adenocarcinoma A549, human cervical cancer Hela cells, human acute leukemia HL-60 cells, and human chronic myeloid leukemia K562 cells using MTT assay as described by Mosmann with modification.^{33,34} Etoposide was taken as a positive control. As shown in Table 1, most of compounds exhibited significant cytotoxicities toward four cancer cell lines with low to moderate micromolar values of IC₅₀. Almost all the compounds showed a cytotoxic selectivity for the HL-60 and K562 cell lines, and several compounds such as **3b**, **3g**, and **3h** displayed a nanomolar level IC₅₀ toward HL-60, which was consistent with etoposide. It was found that the substituent on the benzyl group had a significant effect on cytotoxic activity. Compounds **3b**, **3g**, and **3h** with a strong electron-withdrawing group (–NO₂, –CN, and –CF₃, respectively) on the benzyl ring exhibited the most potent cytotoxic activity against all the tested cancer cell lines with an IC₅₀ ranging between 0.96 and 7.51 μM, 0.71–8.20 μM, and






Fig. 2. Design of carbazole-rhodanine conjugates as novel Topo II inhibitors.



Scheme 1. Synthesis route of carbazole-rhodanine conjugates. Reagents and conditions: (i) DMF, appropriate benzyl bromide, K₂CO₃, rt, 24 h; (ii) POCl₃, DMF, DCM, 0–90 °C, 8 h; (iii) Rhodanine-3-acetic acid, NaOAc, acetic acid, 110 °C, 4 h.

Table 1

Cytotoxic and Topo II inhibition activity of carbazole-rhodanine conjugates.



| Cpd. | R ¹ | IC ₅₀ (μM) | | | | Topo II Inhibition ^a |
|-----------|-------------------|-----------------------|-------|-------|-------|---------------------------------|
| | | Hela | A549 | HL-60 | K562 | |
| 3a | 2-F,4-Br | 11.72 | 9.44 | 3.51 | 6.92 | ++ |
| 3b | 4-NO ₂ | 7.51 | 3.94 | 0.96 | 2.70 | ++ |
| 3c | 4-Br | >50 | >50 | 12.67 | 27.99 | – |
| 3d | 4-F | >50 | >50 | 8.57 | 19.13 | + |
| 3e | 4-CH ₃ | >50 | >50 | 17.81 | 29.60 | – |
| 3f | 4-Cl | 28.30 | 16.18 | 4.86 | 13.36 | – |
| 3g | 4-CN | 5.06 | 2.18 | 0.43 | 1.85 | ++ |
| 3h | 4-CF ₃ | 8.20 | 3.40 | 0.71 | 2.16 | ++ |
| 3i | 3-F,4-F | 15.14 | 12.36 | 4.17 | 7.31 | + |
| 3j | H | >50 | 32.20 | 14.56 | 21.38 | – |
| 3k | 2-F,4-F | >50 | 22.55 | 3.84 | 12.57 | – |
| 3l | 3-F | >50 | 19.80 | 8.29 | 12.84 | – |
| 3m | 2-F | 21.26 | 13.59 | 1.82 | 11.75 | – |
| Etoposide | – | 32.05 | 13.71 | 0.33 | 8.45 | ++ |

^a The relative potency Topo II inhibition of compounds are present as follows: –, no detectable activity at 20 μM; +, weak activity at 20 μM; ++, strong activity at 20 μM.

0.43–5.06 μM, respectively. In the contrast, compounds **3e** with an electron-donating group (–CH₃) on the benzyl ring exhibited poor cytotoxic activity.

Next, these compounds were tested *in vitro* against Topo II using etoposide as positive control and pBR322 DNA as plasmid.^{10–12} The results are present in Fig. 3 and Table 1 showed that most of tested compounds inhibited the Topo II-mediated relaxation of pBR322 DNA at 50 μM (Fig. 3A). Among these compounds, **3a**, **3b**, **3g**, and **3h** displayed strong Topo II inhibition potency at 20 μM (Fig. 3B). Specially, compound **3b** exhibited the most potent Topo II inhibition at 10 μM (Fig. 3C). It was observed that compounds **3b**, **3g**, and **3h** with a strong electron-withdrawing group (–NO₂, CF₃, and –CN, respectively) on the benzyl ring, exhibited better activities than those with a weak electron-withdrawing group (**3c**, **3d**, **3f**, **3i**, **3k**, **3l**, and **3m**). The 4-methyl substitution of the benzyl group (**3e**) did not improve the inhibition activity at all. These results indicated that carbazole-rhodanine conjugates possessed inhibitory activity on Topo II and the substitutions on the benzyl ring with an electron-withdrawing group played an important role on the activity. Topo I-mediated DNA relaxation assay was also carried out to test whether these compounds also target Topo I.^{11,12} Results presented in Fig. 3D showed that camptothecin, a well-known Topo I inhibitor, strongly inhibited Topo I activity, while none of the tested compounds possessed inhibitory activity on Topo I in 100 μM. The result revealed that these compounds selectively inhibited the activity of Topo II.

Topo II inhibitors are classified according to their ability to induce DNA double-strand breaks with (Topo II poisons) or without (Topo II catalytic inhibitors) the formation of a cleaved complex, reflecting different inhibition mechanisms.^{1–3} To gain insight into the mode of action, Topo II-mediated DNA cleavage assay was carried out to verify whether these compounds function as Topo II poisons or Topo II catalytic inhibitors. As shown in Fig. 4A, the well known Topo II poison etoposide produces discrete bands of the linear DNA, corresponding to its poison behavior. In contrast to etoposide, the linear form of the DNA is not visible in **3g** and **3h** even at 50 μM. These observations indicated that the tested compounds function as Topo II catalytic inhibitor.





A**B****C****D**

Fig. 3. (A, B, and C) Topo II inhibition potency of compounds with various concentrations. Lane D, pBR322 DNA; lane T, pBR322 DNA + Topo II; lane E, pBR322 DNA + Topo II + etoposide (100 μM); other lanes, pBR322 DNA + Topo II + compounds. (D) Topo I inhibition potency of compounds. Lane D: pBR322 DNA; lane T: pBR322 DNA + Topo I; lane C: pBR322 DNA + Topo I + camptothecin (100 μM); other lanes: pBR322 DNA + Topo I + compounds (100 μM).

Topo II catalytic inhibitors have two types, namely, DNA intercalators and nonintercalators. In order to determine the intercalating or non-intercalating ability of the leading compounds, a DNA unwinding assay was carried out using supercoiled pBR322 DNA as substrate and ethidium bromide (EB; a classic DNA intercalator)




Fig. 4. (A) Topo II mediated cleavage of plasmid pBR322 DNA. Lane D: pBR322 DNA; lane T: pBR322 DNA + Topo II; lane E: 100 μ M etoposide + Topo II + pBR322 DNA; other lanes: **3g** or **3h** + Topo II + pBR322 DNA. The positions of supercoiled DNA (S), relaxed DNA (R), linear DNA (L), and nicked DNA (N) are indicated. (B) The unwinding assay of **3g** and **3h**. Lane D, pBR322 DNA; lane T, pBR322 DNA + Topo I; other lanes, pBR322 DNA + Topo I + **3g**, **3h**, or EB with different concentrations.

as control. As shown in Fig. 4B, EB is able to transform the relaxed DNA into supercoiled DNA in the presence of excess Topo I. Compounds **3g** and **3h** displayed the similar effect of EB in a dose-dependent manner, suggesting that these compounds are intercalative Topo II catalytic inhibitors.

In conclusion, we have synthesized a series of carbazoles-rhodanine conjugates and evaluated their pharmacological activity. Of the compounds **3a**, **3b**, **3g**, and **3h** could selectively impede Topo II function at 20 μ M without affecting Topo I catalytic activity. Mechanism studies revealed that these compounds might function as intercalative Topo II catalytic inhibitors. These compounds displayed potential cytotoxic activity against four human cancer cell lines. The electron-withdrawing group on the benzyl ring enhancing both enzyme inhibition and cytotoxicity of these compounds. This study may provide valuable information to researchers working on the development of novel antitumor agents targeting Topo II.

Acknowledgements

The authors declare no competing financial interests. This research was supported by National Science Foundation of China (grant number 21272043).

A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.bmcl.2018.03.017>.

References

- Deweese JE, Osheroff N. *Nucleic Acids Res.* 2009;37:738.
- Vos SM, Tretter EM, Schmidt BH, Berger JM. *Nat Rev Mol Cell Biol.* 2011;12:827.
- Pommier Y, Sun Y, Huang SN, Nitiss JL. *Nat Rev Mol Cell Biol.* 2016;17:703.
- Bailly C. *Chem Rev.* 2012;112:3611.
- Tewey KM, Chen GL, Nelson EM, Liu LF. *J Biol Chem.* 1984;259:9182.
- Li B, Yue ZZ, Feng JM, He Q, Miao ZH, Yang CH. *Eur J Med Chem.* 2013;66:531.
- Ezoe S. *Int J Environ Res Public Health.* 2012;9:2444.
- Mordente A, Meucci E, Martorana GE, Tavian D, Silvestrini A. *Curr Med Chem.* 2017;24:1607–1626.
- Vann KR, Ergün Y, Topcu Z, Oncuoglu S, Osheroff N, Topcu Z. *Bioorg Med Chem Lett.* 2016;26:1809.
- Huang ZH, Zhuo ST, Li CY, et al. *Eur J Med Chem.* 2013;68:58.
- Yao BL, Mai YW, Chen SB, et al. *Eur J Med Chem.* 2015;92:540.
- Zhuo ST, Li CY, Hu MH, et al. *Org Biomol Chem.* 2013;11:3989.
- Islam MS, Park S, Song C, Kadi AA, Kwon Y, Rahman AF. *Eur J Med Chem.* 2017;125:49.
- Minniti E, Byl JAW, Riccardi L, et al. *Bioorg Med Chem Lett.* 2017;27:4687.
- Morphy R, Rankovic Z. *J Med Chem.* 2005;48:6523.
- Onda Y, Masuda Y, Yoshida M, Doi T. *J Med Chem.* 2018;61:1375.
- Chaniyara R, Tala S, Chen CW, et al. *J Med Chem.* 2013;56:1544.
- Infante LL, Sledge A, Laradji A, Okoro CO, Osheroff N. *Bioorg Med Chem Lett.* 2017;27:586.
- Hueso-Falcón I, Amesty Á, Anaissi-Afonso L, Lorenzo-Castrillejo I, Machín F, Estévez-Braun A. *Bioorg Med Chem Lett.* 2017;27:484.
- Li PH, Zeng P, Chen SB, et al. *J Med Chem.* 2016;59:238.
- Li PH, Hong J, Zhang WJ, et al. *Eur J Med Chem.* 2018;145:498.
- Tsutsumi LS, Gundisch D, Sun DQ. *Curr Top Med Chem.* 2016;16:1290.
- Wang WS, Sun X, Sun D, et al. *ChemMedChem.* 2016;11:2675.
- Chen Q, Chen W, Fan W, et al. *Bioorg Med Chem Lett.* 2016;26:5065.
- Funayama Y, Nishio K, Wakabayashi K, et al. *Mutat Res.* 1996;349:183.
- Hajbi Y, Neagoie C, Biannic B, et al. *Eur J Med Chem.* 2010;45:5428.
- Mahapatra DK, Bharti SK, Asati V. *Eur J Med Chem.* 2015;98:69.
- Mendgen T, Steuer C, Klein CD. *J Med Chem.* 2012;55:743.
- Min G, Lee SK, Kim HN, et al. *Bioorg Med Chem Lett.* 2013;23:3769.
- Liu K, Rao W, Parikh H, et al. *Eur J Med Chem.* 2012;47:125.
- Priyadarshani G, Nayak A, Amrutkar SM, et al. *ACS Med Chem Lett.* 2016;7:1056.
- Sun H, Tawa G, Wallqvist A. Classification of scaffold-hopping approaches. *Drug Discov Today.* 2012;17:310.
- Mosmann TJ. *J Immunol Methods.* 1983;65:55.
- Nitiss JL. *Nat Rev Cancer.* 2009;9:338.